Knowledge Leaders Capital LLC increased its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 0.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,144 shares of the medical research company’s stock after buying an additional 196 shares during the period. Laboratory Corporation of America Holdings makes up approximately 2.7% of Knowledge Leaders Capital LLC’s holdings, making the stock its 24th largest position. Knowledge Leaders Capital LLC’s holdings in Laboratory Corporation of America Holdings were worth $4,184,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LH. CFO4Life Group LLC bought a new stake in Laboratory Corporation of America Holdings during the first quarter valued at $312,000. Oxford Asset Management raised its stake in Laboratory Corporation of America Holdings by 68.6% in the first quarter. Oxford Asset Management now owns 51,622 shares of the medical research company’s stock valued at $7,406,000 after buying an additional 21,003 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Laboratory Corporation of America Holdings by 2.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,900 shares of the medical research company’s stock valued at $1,420,000 after buying an additional 199 shares in the last quarter. Elkfork Partners LLC raised its stake in Laboratory Corporation of America Holdings by 2.4% in the first quarter. Elkfork Partners LLC now owns 12,936 shares of the medical research company’s stock valued at $1,856,000 after buying an additional 308 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in Laboratory Corporation of America Holdings by 55.5% in the first quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock valued at $3,961,000 after buying an additional 9,857 shares in the last quarter. Institutional investors own 91.64% of the company’s stock.

Shares of Laboratory Corporation of America Holdings (LH) opened at 153.91 on Monday. The company has a market capitalization of $15.67 billion, a price-to-earnings ratio of 21.56 and a beta of 0.94. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22. The company’s 50-day moving average price is $155.89 and its 200-day moving average price is $145.06.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.40 by $0.07. The firm had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.36 earnings per share. Equities research analysts forecast that Laboratory Corporation of America Holdings will post $9.50 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/21/knowledge-leaders-capital-llc-has-4-18-million-position-in-laboratory-corporation-of-america-holdings-lh.html.

LH has been the topic of several analyst reports. ValuEngine lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. Jefferies Group LLC lowered their price objective on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating on the stock in a research note on Friday, April 28th. Barclays PLC upped their price objective on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. BidaskClub upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a research note on Sunday, May 28th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $159.75.

In related news, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total value of $951,657.28. Following the transaction, the chief financial officer now owns 18,122 shares in the company, valued at $2,889,734.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director R Sanders Williams sold 3,100 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $156.88, for a total transaction of $486,328.00. Following the completion of the transaction, the director now owns 10,073 shares in the company, valued at approximately $1,580,252.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,068 shares of company stock worth $2,237,985. Insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.